Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: Eligibility criteria for NMA_Diabetes - JSON Representation

Raw json | Download

{
  "resourceType" : "Group",
  "id" : "264323",
  "meta" : {
    "versionId" : "16",
    "lastUpdated" : "2024-08-01T12:27:35.568Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-eligibility-criteria"
    ]
  },
  "text" : {
    "status" : "empty",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No data.]</div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-author",
      "valueContactDetail" : {
        "name" : "Sheyu Li"
      }
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact",
      "valueRelatedArtifact" : {
        "type" : "cite-as",
        "citation" : "Eligibility criteria for NMA_Diabetes [Database Entry: FHIR Group Resource]. Contributors: Sheyu Li [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 264323. Revised 2024-07-30. Available at: https://fevir.net/resources/Group/264323. Computable resource at: https://fevir.net/resources/Group/264323."
      }
    }
  ],
  "url" : "https://fevir.net/resources/Group/264323",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net",
      "value" : "264323",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "title" : "Eligibility criteria for NMA_Diabetes",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "description" : "Eligible randomised controlled trials compared drugs used to treat adults with type 2 diabetes. We considered the following drug classes: SGLT-2 inhibitors, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, α-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists. Appendix 1.3 describes the detailed drug names and definitions of control arms (typically standard treatment at the time the trials were conducted, representing the treatment regimens the patient received before the clinician considered adding a new drug). Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug treatment, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible.",
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "membership" : "conceptual",
  "code" : {
    "text" : "Research study"
  },
  "combinationMethod" : "all-of",
  "characteristic" : [
    {
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/181513",
            "code" : "SEVCO:01000",
            "display" : "Study Design"
          }
        ],
        "text" : "Study design"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://hl7.org/fhir/study-design",
            "code" : "SEVCO:01003",
            "display" : "randomized assignment"
          }
        ]
      },
      "exclude" : false,
      "description" : "The study design is a randomised controlled trial."
    },
    {
      "code" : {
        "text" : "Study population"
      },
      "valueReference" : {
        🔗 "reference" : "Group/265093",
        "type" : "Group",
        "display" : "Adults with type 2 diabetes"
      },
      "exclude" : false,
      "description" : "All the participants are adults with type 2 diabetes."
    },
    {
      "code" : {
        "text" : "Study interventions"
      },
      "valueReference" : {
        🔗 "reference" : "Group/265092",
        "type" : "Group",
        "display" : "Diabetes treatment medication"
      },
      "exclude" : false,
      "description" : "The medication class should be among one or more of SGLT-2 inhibitors, GLP-1 receptr agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones, sulfonylureas, metformin, α-glucosidase inhibitors, meglitinides, insulins, dual GIP/GLP-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists."
    },
    {
      "code" : {
        "text" : "Duration of follow up"
      },
      "valueQuantity" : {
        "value" : 24,
        "comparator" : ">=",
        "unit" : "weeks",
        "system" : "http://unitsofmeasure.org",
        "code" : "wk"
      },
      "exclude" : false,
      "description" : "Eligible trials had a follow-up of 24 weeks or longer."
    },
    {
      "code" : {
        "text" : "Language of publication"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "urn:ietf:bcp:47",
            "code" : "en",
            "display" : "English"
          }
        ]
      },
      "exclude" : false,
      "description" : "We excluded non-English language published studies."
    },
    {
      "code" : {
        "text" : "Defined by CodeableConcept"
      },
      "valueCodeableConcept" : {
        "text" : "Systematically comparing combinations of more than one drug treatment class with no drug treatment"
      },
      "exclude" : true,
      "description" : "We excluded trials systematically comparing combinations of more than one drug treatment class with no drug treatment."
    },
    {
      "code" : {
        "text" : "Defined by CodeableConcept"
      },
      "valueCodeableConcept" : {
        "text" : "Subgroup analyses"
      },
      "exclude" : true,
      "description" : "We excluded subgroup analyses of randomised controlled trials."
    }
  ]
}